Table 5. Multivariate cox regression analysis of TTP and OS.
| Characteristics | TTP | OS | |||||
|---|---|---|---|---|---|---|---|
| Total | 2nd line regimen | ||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||
| Rapid desensitization of carboplatin | 0.733 (0.320–1.680) | 0.463 | 1.945 (0.476–7.951) | 0.355 | 1.310 (0.432–3.974) | 0.634 | |
| Age (yr) | 1.010 (0.960–1.063) | 0.700 | 1.042 (0.970–1.121) | 0.262 | 0.942 (0.871–1.019) | 0.138 | |
| Time to relapse (mon) | 0.970 (0.943–0.999) | 0.042 | 0.885 (0.809–0.967) | 0.007 | 0.952 (0.909–0.998) | 0.040 | |
| Previous chemotherapy cycle (number) | 1.086 (1.024–1.151) | 0.006 | 0.983 (0.882–1.096) | 0.759 | 0.988 (0.913–1.069) | 0.767 | |
| ECOG PS | |||||||
| 1 | 1.302 (0.399–4.250) | 0.661 | 2.832 (0.385–20.841) | 0.669 | 1.776 (0.208–15.163) | 0.600 | |
| 2 | 1.840 (0.437–7.744) | 0.405 | 8.674 (0.843–89.314) | 0.101 | 3.734 (0.307–45.415) | 0.301 | |
| Concurrent chemotherapeutic drug (gemcitabine) | 2.018 (0.696–5.849) | 0.196 | 3.356 (0.783–14.391) | 0.103 | 0.652 (0.194–2.191) | 0.489 | |
TTP, time to progression; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status.